
Asundexian Cuts Stroke Risk by 26% With No Rise in Major Bleeding, Bayer Reports
Bayer’s Asundexian Demonstrated a Substantial 26% Reduction in Stroke After a Non-Cardioembolic Ischemic Stroke or High-Risk Transient Ischemic Attack, With No Increase in ISTH Major Bleeding Versus Placebo Bayer today…












